• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
‘Truly Sorry’: Scientists Pull Panned Lancet Study of Trump-Touted Drug

‘Truly Sorry’: Scientists Pull Panned Lancet Study of Trump-Touted Drug

June 5, 2020
MANISHA SINGH: No Great Expectations Of The Group Of Seven

MANISHA SINGH: No Great Expectations Of The Group Of Seven

June 20, 2025
Court Decision Could Spell Disaster For DC Law Allowing Noncitizens Ability To Vote

Court Decision Could Spell Disaster For DC Law Allowing Noncitizens Ability To Vote

June 20, 2025
Industries Long Addicted To Illegal Labor In Withdrawal As Trump Cracks Down

Industries Long Addicted To Illegal Labor In Withdrawal As Trump Cracks Down

June 20, 2025
Obama-Appointed Judge Allows Harvard To Continue Enrolling Foreign Students

Obama-Appointed Judge Allows Harvard To Continue Enrolling Foreign Students

June 20, 2025
Trump Admin Gives California Ultimatum To Cut Trans Ideology From Classrooms

Trump Admin Gives California Ultimatum To Cut Trans Ideology From Classrooms

June 20, 2025
‘The View’ Hosts Blame Sunny Hostin For Harris Losing Election With Viral Question 

‘The View’ Hosts Blame Sunny Hostin For Harris Losing Election With Viral Question 

June 20, 2025
Jamie Raskin Still Refuses To Condemn Squad Member For Using Antisemitic Slogan

Jamie Raskin Still Refuses To Condemn Squad Member For Using Antisemitic Slogan

June 20, 2025
Man Charged With Ethnic Intimidation After Allegedly Threatening Jewish Congressman With Palestine Flag

Man Charged With Ethnic Intimidation After Allegedly Threatening Jewish Congressman With Palestine Flag

June 20, 2025
China Tries Getting Rich In America’s Backyard

China Tries Getting Rich In America’s Backyard

June 20, 2025
Harry Reid-Appointed Official Puts Key Parts Of Trump Bill On Chopping Block

Harry Reid-Appointed Official Puts Key Parts Of Trump Bill On Chopping Block

June 20, 2025
ANNE CANFIELD And JAMES CARTER: It’s Time To Modernize The Capital Gains Exclusion For Home Sales

ANNE CANFIELD And JAMES CARTER: It’s Time To Modernize The Capital Gains Exclusion For Home Sales

June 20, 2025
Trump May Have Secret Weapon To Ram DOGE Cuts Past Timid GOP Senators

Trump May Have Secret Weapon To Ram DOGE Cuts Past Timid GOP Senators

June 20, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Friday, June 20, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home News

‘Truly Sorry’: Scientists Pull Panned Lancet Study of Trump-Touted Drug

by Reuters
June 5, 2020
in News
247 5
5
‘Truly Sorry’: Scientists Pull Panned Lancet Study of Trump-Touted Drug

FILE PHOTO: The drug hydroxychloroquine, pushed by U.S. President Donald Trump and others in recent months as a possible treatment to people infected with the coronavirus disease (COVID-19), is displayed by a pharmacist at the Rock Canyon Pharmacy in Provo, Utah, U.S., May 27, 2020. REUTERS/George Frey

491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

An influential study that found hydroxychloroquine increased the risk of death in COVID-19 patients has been withdrawn a week after it led to major trials being halted, adding to confusion about a malaria drug championed by U.S. President Donald Trump.

The Lancet medical journal pulled the study after three of its authors retracted it, citing concerns about the quality and veracity of data in it. The World Health Organization (WHO) will resume its hydroxychloroquine trials after pausing them in the wake of the study. Dozens of other trials have resumed or are in process.

The three authors said Surgisphere, the company that provided the data, would not transfer the dataset for an independent review and they “can no longer vouch for the veracity of the primary data sources.”

The fourth author of the study, Dr. Sapan Desai, chief executive of Surgisphere, declined to comment on the retraction.

The Lancet said it “takes issues of scientific integrity extremely seriously” adding: “There are many outstanding questions about Surgisphere and the data that were allegedly included in this study”.

Another study in the New England Journal of Medicine (NEJM) that used Surgisphere data and shared the same lead author, Harvard Medical School Professor Mandeep Mehra, was retracted for the same reason.

The Lancet said reviews of Surgisphere’s research collaborations were urgently needed.

The race to understand and treat the new coronavirus causing the COVID-19 pandemic has accelerated the pace of research and peer-reviewed scientific journals are go-to sources of information for doctors, policymakers and lay people alike.

Chris Chambers, a professor of psychology and an expert at the UK Center for Open Science, said The Lancet and the NEJM – which he described as “ostensibly two of the world’s most prestigious medical journals” – should investigate how the studies got through peer review and editorial checks.

“The failure to resolve such basic concerns about the data” raises “serious questions about the standard of editing” and about the process of peer review, he said.

The Lancet did not immediately respond to a Reuters request for comment. The NEJM could not immediately be reached for comment.

UNANSWERED QUESTIONS

The observational study published in The Lancet on May 22 said it looked at 96,000 hospitalized COVID-19 patients, some treated with the decades-old malaria drug. It claimed that those treated with hydroxychloroquine or the related chloroquine had higher risk of death and heart rhythm problems than patients who were not given the medicines.

“I did not do enough to ensure that the data source was appropriate for this use,” the study’s lead author, Professor Mehra, said in a statement. “For that, and for all the disruptions – both directly and indirectly – I am truly sorry.”

Many scientists voiced concern about the study, which had already been corrected last week because some location data was wrong. Nearly 150 doctors signed an open letter to The Lancet calling the article’s conclusions into question and asking to make public the peer review comments that preceded publication.

Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine said the retraction decision was “correct” but still left unanswered the question about whether hydroxychloroquine is effective in COVID-19.

“It remains the case that the results from randomised trials are necessary to draw reliable conclusions,” he said.

(Reporting by Michael Erman, Peter Henderson, Kate Kelland and Josephine Mason; Editing by Leslie Adler, Tom Brown, Giles Elgood and Carmel Crimmins)

Tags: Coronavirus Outbreak
Share196Tweet123
Reuters

Reuters

Reuters is an international news organization.

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th